Melanostatin DM (MIF-1)

Melanostatin (MIF-1, Pro-Leu-Gly-NH2) is a naturally occurring tripeptide that functions as a melanocyte-stimulating hormone release-inhibiting factor and dopamine modulator. The peptide has demonstrated effects on mood, motivation, and cognitive function through its interactions with dopamine receptor systems. Research indicates MIF-1 opposes some effects of melanocyte-stimulating hormone (MSH) peptides and may modulate the activity of opioid systems. Studies show potential antidepressant and anti-parkinsonian effects, possibly through enhancement of dopaminergic transmission. The peptide has been investigated for its effects on opiate tolerance and withdrawal, suggesting utility in addiction medicine. Research demonstrates MIF-1 may reduce the development of tolerance to morphine and attenuate withdrawal symptoms. The tripeptide is resistant to enzymatic degradation and can cross the blood-brain barrier. Clinical studies have explored applications in depression, Parkinson's disease, and substance dependence, though results have been variable. MIF-1 represents an interesting endogenous peptide with multiple neuromodulatory effects that continue to be investigated.

Human evidence is decades old, small-scale, and inconsistent (positive depression signal, negative Parkinson's signal); no modern large trials; the 'DM' variant designation is not validated in the literature; no regulatory approval.

Naturally occurring hypothalamic tripeptide Pro-Leu-Gly-NH2 (MIF-1/melanostatin); reported to modulate dopaminergic signaling and oppose some alpha-MSH actions; resistant to enzymatic degradation and can cross the blood-brain barrier. Research-stage only.